Glucocorticoids and treatment of prostate cancer: a preclinical and clinical review

Urology. 2002 Oct;60(4):553-61. doi: 10.1016/s0090-4295(02)01741-7.

Authors

Marwan Fakih¹, Candace S Johnson, Donald L Trump

Affiliation

¹ Department ofMedicine, Division of Hematology-Oncology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.

PMID: 12385906
DOI: 10.1016/s0090-4295(02)01741-7

No abstract available

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Adenocarcinoma / drug therapy
Adenocarcinoma / metabolism
Androgen Antagonists / metabolism
Androgen Antagonists / pharmacology
Androgen Antagonists / therapeutic use
Annexins / drug effects
Annexins / metabolism
Antineoplastic Agents, Hormonal / pharmacology
Antineoplastic Agents, Hormonal / therapeutic use*
Apoptosis / drug effects
Cell Division / drug effects
Clinical Trials as Topic
Clinical Trials, Phase II as Topic
Clinical Trials, Phase III as Topic
Glucocorticoids / pharmacology
Glucocorticoids / therapeutic use*
Humans
Male
Neoplasms, Hormone-Dependent / drug therapy
Neoplasms, Hormone-Dependent / metabolism
Neoplasms, Hormone-Dependent / physiopathology
Prostatic Neoplasms / drug therapy*
Prostatic Neoplasms / metabolism
Prostatic Neoplasms / physiopathology
Retrospective Studies
Transcription, Genetic / drug effects
Transforming Growth Factor beta / drug effects
Transforming Growth Factor beta / metabolism
Treatment Outcome
Tumor Cells, Cultured

Substances

Androgen Antagonists
Annexins
Antineoplastic Agents, Hormonal
Glucocorticoids
Transforming Growth Factor beta